MiMedx Group (Nasdaq: MDXG) and Sanara MedTech (Nasdaq: SMTI) announced Wednesday they have entered into a definitive merger agreement under which MiMedx will acquire all outstanding shares of Sanara in a cash and stock transaction valued at $35 per share, implying a total enterprise value of approximately $350 million. Sanara shareholders will receive $33.00 in cash plus 0.4735 shares of MiMedx common stock for each share owned, a combination representing a 46% premium to Sanara’s 30-day volume-weighted average price. The boards of both companies have unanimously approved the transaction, with closing expected by the end of 2026.
MiMedx plans to fund the cash portion of the deal through existing cash on hand alongside a new $300 million term loan secured with Hayfin Capital Management. The company’s existing credit agreement will be terminated and repaid in full at closing.
What Sanara Brings to the Table
Sanara MedTech is focused entirely on developing and commercializing regenerative products for surgical markets, an area MiMedx has identified as its primary strategic growth priority. Sanara contributes more than $100 million in surgical revenue along with a high-margin, 510(k)-cleared product portfolio, meaningfully expanding MiMedx’s presence in a segment where the company was already seeing meaningful traction on its own. MiMedx’s Surgical product sales grew 15% year over year in the second quarter to $39.3 million, driven by strength in its AmnioFix and AmnioEffect product lines along with early contributions from newer offerings.
Once combined, management expects the transaction to nearly double MiMedx’s surgical revenue and push combined company revenue above $400 million, with an adjusted EBITDA margin target above 20%. The deal is expected to be immediately accretive to revenue growth, gross margin, and adjusted EBITDA margin, and management anticipates more than $20 million in run-rate cost synergies.
The Balance Sheet Behind the Deal
The acquisition arrives alongside MiMedx’s second quarter results, which showed net sales of $64 million and a net loss of $14.8 million for the period. Despite that quarterly loss, the company ended the quarter with $135.8 million in cash and $119 million in net cash, and it reiterated full-year 2026 net sales guidance of $260 million to $290 million on a standalone basis. MiMedx also completed a cost reduction program targeting approximately $40 million in annualized savings and repurchased 3.5 million shares for roughly $13 million during the quarter, signaling a company managing its existing operations tightly even while pursuing a transformational acquisition.
Why This Matters for Small Cap Medtech Investors
For investors tracking regenerative medicine and surgical device companies in the small cap space, this deal reflects a broader consolidation pattern taking hold across specialized medtech niches. Companies with focused, high-margin surgical product portfolios but limited standalone scale are increasingly attractive targets for larger platforms looking to build a genuinely differentiated position across surgical subspecialties rather than compete purely on breadth. MiMedx is explicitly betting that combining two complementary regenerative medicine portfolios creates more value together than either company could generate independently, and the debt-financed structure of the deal signals real conviction in that combined growth trajectory.